S-1/A: Envoy Medical Launches $25M Offering Amid Nasdaq Delisting Fears

Envoy Medical, Inc. announces a new public offering of up to $25 million in Class A Common Stock and Warrants to fund its pivotal clinical study, while facing Nasdaq compliance challenges.

Summary

• Envoy Medical, Inc. is offering up to 47,169,811 shares of Class A Common Stock, up to 47,169,811 Pre-Funded Warrants, up to 28,301,886 Series A-1 Warrants, up to 47,169,811 Series A-2 Warrants, and Placement Agent Warrants for up to 3,301,886 shares.
• The assumed combined public offering price is $0.53 per share of Common Stock and accompanying Common Warrants.
• Pre-Funded Warrants have an exercise price of $0.0001 per share and are immediately exercisable.
• Series A-1 Warrants have an assumed exercise price of $0.53 and expire on the earlier of 24 months post-Stockholder Approval Date or 30 days after public announcement of PMA submission (Milestone 1).
• Series A-2 Warrants have an assumed exercise price of $0.53 and expire on the earlier of 60 months post-Stockholder Approval Date or 30 days after public announcement of FDA approval (Milestone 2).
• Placement Agent Warrants have an assumed exercise price of $0.6625 (125% of the offering price).
• The estimated net proceeds from this offering, assuming maximum sale, are approximately $23.0 million, intended for working capital and general corporate purposes to fund the FDA pivotal clinical study.
• The company reported net losses of $17.170 million for the nine months ended September 30, 2025, and $16.177 million for the nine months ended September 30, 2024.
• The accumulated deficit stood at $305.659 million as of September 30, 2025, and $284.734 million as of December 31, 2024.
• Cash on hand was $3.556 million as of September 30, 2025.
• The FDA approved the advancement of the Acclaim CI pivotal clinical trial to its second and final stage on October 3, 2025, with 30 out of 46 participants enrolled in the final cohort.
• The company received a Nasdaq notice of non-compliance with the $35 million market value of listed securities (MVLS) requirement on February 25, 2025, and was granted an exception until February 23, 2026.
• A further Nasdaq notice of non-compliance with the $1.00 minimum bid price requirement was received on November 19, 2025, with an initial compliance period until May 18, 2026.
• Previous capital raises include $2.5 million gross from a September 2025 offering and $4.0 million gross from an October 2025 offering.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk investment due to significant ongoing losses, Nasdaq compliance issues, and the early stage of its primary product candidate, despite promising clinical trial progress and a unique product concept. The substantial capital raise is critical for continued operations but also highlights the company's precarious financial position.

Positives

• The Acclaim CI received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.
• The FDA approved the advancement of the Acclaim CI pivotal clinical trial to its second and final stage on October 3, 2025, based on preliminary data.
• No serious adverse events or unanticipated device effects were reported from the first 10 study participants in the Acclaim CI clinical trial.
• The Acclaim CI is designed as a fully implanted cochlear implant, offering potential competitive advantages such as 24-hour use, hearing in water, reduced battery maintenance, and potentially reduced social stigma.
• The cochlear implant market has established market acceptance and reimbursement pathways, which could benefit the Acclaim CI upon approval.
• The company holds a significant intellectual property portfolio with 39 issued U.S. patents and 47 issued foreign patents related to its hearing technologies.
• The 'Hearing Device Coverage Clarification Act' introduced in February 2024 could reclassify the Esteem FI-AMEI as a prosthetic, potentially enabling reimbursement and commercial viability for the existing FDA-approved product.

Negatives

• The company has a history of significant net losses, reporting $(17.170) million for the nine months ended September 30, 2025, and an accumulated deficit of $(305.659) million.
• The company expects to continue incurring significant net losses and increasing operating expenses for the foreseeable future.
• The Acclaim CI has not yet been approved for sale, and no product sales are expected until regulatory approval is obtained.
• The Esteem FI-AMEI, the company's first product, failed to gain commercial traction primarily due to a lack of reimbursement or insurance coverage.
• The company is not in compliance with Nasdaq's $35 million market value of listed securities requirement (exception until February 23, 2026) and the $1.00 minimum bid price requirement (compliance period until May 18, 2026).
• An Early Feasibility Study (EFS) for the Acclaim CI identified a signal-to-noise issue, creating an 'unintended noise' (gurgling or sizzling background noise), which requires ongoing mitigation and resolution strategies.
• Material weaknesses in internal control over financial reporting were identified for the years ended December 31, 2024, and 2023.
• The company's financial statements contain an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern.
• The public float of the company's Common Stock is very illiquid, approximately $9.7 million as of January 30, 2026, which could negatively impact the stock price from significant sales.
• The company is highly dependent on key members of its executive management team, and their loss could impede business plans.
• The management team has limited experience managing a publicly traded company, potentially straining resources and diverting attention.

Risks

• The market price of Common Stock has been and may continue to be extremely volatile, potentially causing substantial losses for investors.
• The public float of Common Stock is very illiquid, and there may not be sufficient demand to absorb the sale of newly registered shares, potentially causing a significant negative impact on the price.
• Investors may experience future dilution as a result of future equity offerings.
• The company may be subject to securities litigation, which is expensive and could divert management attention.
• Failure to meet Nasdaq's continued listing requirements could result in a delisting of Common Stock.
• The company is an early-stage company with a history of losses and may not achieve profitability in the future.
• Substantial additional funding will be needed, which may not be available on acceptable terms or at all, potentially requiring curtailment or discontinuation of product development.
• Clinical failure can occur at any stage of clinical development, and current clinical experience does not guarantee future favorable results or regulatory approval for Acclaim CI.
• The company operates in a very competitive business environment, and inability to compete successfully could adversely affect business and financial results.
• Inability to successfully commercialize the Acclaim CI, or any subsequent decline in demand, could severely harm revenue generation.
• Estimates of the addressable market for the product may be inaccurate or smaller than anticipated.
• The company depends on third parties to manage preclinical studies and clinical trials, which may lead to costs and delays beyond its control.
• The company may become a defendant in stockholder derivative, class-action, and other litigation, which could adversely affect business and financial condition.
• If the company is unable to obtain significant patent protection or if intellectual property rights do not adequately protect products, it may be unable to gain significant market share.
• Obtaining and maintaining patent protection depends on compliance with various procedural requirements, and non-compliance could reduce or eliminate patent protection.
• Patent terms may not be sufficient to effectively protect products and business for an adequate period.
• The company may be subject to claims of misappropriating third-party intellectual property or breaching non-competition agreements.
• Failure of a key information technology system, process, or site, including cybersecurity breaches, could adversely affect the business.
• Unfavorable global economic conditions, such as inflation and rising interest rates, could adversely affect the business and ability to raise capital.
• The successful commercialization of Acclaim CI depends on governmental authorities and health insurers establishing coverage, adequate reimbursement levels, and favorable pricing policies.
• If healthcare professionals do not recommend the product to their patients, Acclaim CI may not achieve market acceptance.
• The company will be dependent upon contract manufacturing organizations and material suppliers, making it vulnerable to supply shortages, increased costs, and quality issues.
• The company has broad discretion in the use of net proceeds from the offering and may not use them effectively.
• New investors will experience immediate and substantial dilution in the net tangible book value per share.
• Resales of Common Stock in the public market by existing stockholders during the offering may cause the market price to fall.
• There is no public market for the Pre-Funded Warrants or Common Warrants, limiting their liquidity.
• The Common Warrants are speculative in nature, and there is no assurance the market value of Common Stock will equal or exceed their exercise price.
• Holders of Pre-Funded Warrants and Common Warrants will have no rights as a stockholder until exercise.
• This is a reasonable best efforts offering with no minimum amount of securities required to be sold, meaning the company may receive substantially less than the maximum proceeds.
• Investors in this offering will not receive a refund if the company does not sell sufficient securities to pursue its business goals.

Future Outlook

Envoy Medical anticipates obtaining FDA approval for its Acclaim CI in late 2027 or early 2028, with a potential extension to the first half of 2028 if a panel review is requested. The company expects to continue incurring significant and increasing operating losses for the foreseeable future as it advances clinical development and prepares for commercialization. The commercialization strategy for Acclaim CI will prioritize 'quality over quantity,' initially targeting approximately 30 surgical sites and gradually expanding. Following FDA approval, the company plans to pursue the CE Mark in the European Union and then other international markets. Research and development efforts will focus on improving the existing Acclaim CI design, robust software, and user interfaces.

Management Comments

• "Our vision is to create fully implanted hearing devices that leverage the natural ear not an artificial microphone to pick up sound."
• "We believe that the Acclaim CI is a first-of-its-kind cochlear implant."
• "We believe that Acclaim CI gives us the opportunity to disrupt the existing cochlear implant market."
• "We believe that the fully implanted nature of the Acclaim CI will facilitate an increase in daily usage over other types of cochlear implants because the device can be used 24-hours a day."
• "We believe we can increase penetration rates for adult cochlear implants in the U.S."
• "Moreover, it is reasonable to believe that Acclaim CI will demand a higher average selling price than existing partially implanted cochlear implants."
• "Our commercialization strategy will be quality over quantity to facilitate the Acclaim CI gaining a meaningful foothold in the marketplace without unnecessary complications stemming from attempting to grow too quickly."
• "We believe we may be able to correct the issue [signal-to-noise] without material delay, but there remains the possibility that once one noise source is corrected another will be uncovered and the timelines may be extended in a material way."
• "Management believes that its existing cash balances combined with future capital raises through debt and equity and cash receipts from product sales will be sufficient to fund ongoing operations through at least one year from the date the unaudited condensed consolidated financial statements are issued."
• "The Company believes that the lawsuit is meritless and has been defending this matter vigorously."

Industry Context

StockSavvy.ai notes that Envoy Medical operates in the highly competitive hearing health industry, specifically targeting the cochlear implant market. This market is currently dominated by a few major players like Cochlear Ltd., Advanced Bionics (Sonova), and Med-El. Envoy Medical aims to differentiate itself with the Acclaim CI, a fully implanted device that leverages the natural ear, aligning with broader industry trends towards enhanced usability, connectivity, lifestyle integration, and miniaturization. The market for cochlear implants is expanding due to evolving candidacy requirements and increased awareness, presenting a significant opportunity for new technologies, provided regulatory hurdles and market acceptance are successfully navigated.

Comparison to Industry Standards

• The Acclaim CI is positioned as a 'first-of-its-kind' fully implanted cochlear implant, offering a distinct advantage over traditional partially implanted devices from competitors like Cochlear Ltd., Advanced Bionics (Sonova), and Med-El by eliminating external components.
• The Esteem FI-AMEI is the only FDA-approved fully implanted active middle ear hearing device in the U.S. market, but its commercial failure due to lack of reimbursement highlights a key challenge that the Acclaim CI aims to overcome by targeting the established cochlear implant reimbursement pathways.
• The company's market research estimates a 5-8% penetration rate for cochlear implants in the adult population, indicating a substantial untapped market compared to current industry utilization, which Envoy Medical believes its fully implanted device can capture.
• Envoy Medical anticipates the Acclaim CI will command a higher average selling price (assumed $30,000) compared to current partially-implanted devices (average $25,000), reflecting its innovative fully implanted design and perceived benefits.
• The company's patent portfolio, with 39 issued U.S. patents and 47 issued foreign patents, is a significant asset in an industry where intellectual property is crucial for competitive advantage against established players.

Management Changes

Corporate Governance

Legal Proceedings

• A lawsuit was filed on November 14, 2023, by Atlas Merchant Capital SPAC Fund I LP against the company, former CEO Whitney Haring-Smith, former CFO Daniel Hirsch, and Anzu SPAC GP I LLC. Atlas alleges it was not allowed to redeem its shares and seeks approximately $9.4 million in damages. The company believes the lawsuit is meritless and is defending it vigorously. A motion to dismiss was partially granted on March 3, 2025, narrowing the claims.
• Previous lawsuits by Spearman Plaintiffs (January 2020, February 2020) alleging self-dealing by the controlling stockholder and directors were settled on September 15, 2023. The settlement involved the transfer of the plaintiffs' stock holdings to an entity affiliated with the majority stockholder, with no payment required from the company.

Related Party Transactions

• Term Loans: GAT Funding, LLC (controlled by Glen A. Taylor, a former director and controlling stockholder) provided $30.0 million in term loans (February 2024, August 2024, and March 2025 Term Loans). These loans, including principal and accrued interest, were forgiven on August 25, 2025, in exchange for a $100,000 payment from the company and an extension of the Term Loan Warrants' expiration date to December 31, 2028.
• Facility Lease: The company leases its headquarters office space in Minnesota from Taylor Corporation, an entity controlled by Glen Taylor. The lease term extends through December 31, 2030, with $220,000 paid in 2024 for rent and shared expenses.
• Shared Services Arrangement: The company has an arrangement with a company indirectly owned by Glen Taylor for support services, with expenses of less than $100,000 for the nine months ended September 30, 2025, and 2024.
• Consulting Agreement: The company entered into a consulting agreement with Oasis Business Consulting, LLC (owned by Interim Chief Financial Officer Robert Potashnick) on June 23, 2025, for his services at $200 per hour, with expenses of $95,000 for the nine months ended September 30, 2025.
• Sponsor Induced Conversion: On December 20, 2024, the Sponsor (Anzu SPAC GP I LLC) waived $3.7 million in accrued dividends on Series A Preferred Stock and the vesting restrictions on 1,000,000 Contingent Sponsor Shares. In return, 373,333 shares of Series A Preferred Stock were converted into 1,028,986 shares of Common Stock at a reduced conversion price of $3.63 per share.

Stakeholder Impact

• Shareholders: Will experience immediate and substantial dilution from the current offering. The volatile stock price and Nasdaq compliance issues pose significant risks to their investment value. The potential for future value creation hinges on the successful development and commercialization of the Acclaim CI.
• Employees: The company's continued operations and development efforts, supported by the capital raise, are crucial for job security and potential growth opportunities. Stock-based compensation plans are in place to incentivize personnel.
• Customers (Patients): The development of the Acclaim CI offers the prospect of an innovative, fully implanted hearing solution with potential lifestyle benefits. Existing Esteem FI-AMEI patients will continue to receive support.
• Suppliers: Increased demand for components for the Acclaim CI clinical trials and future commercialization could benefit suppliers, but reliance on single-source suppliers introduces risks of disruption.
• Creditors: The forgiveness of $30.0 million in term loans from a related party significantly reduced the company's debt burden. The current capital raise provides necessary liquidity to fund operations.

Next Steps

• Continue the Acclaim CI pivotal clinical study, enrolling the remaining 16 participants in the final cohort.
• Collect and analyze 12-month follow-up data from all 56 Acclaim CI study participants.
• Submit a Premarket Approval (PMA) application to the FDA for the Acclaim CI.
• Address and resolve the identified signal-to-noise issue in the Acclaim CI design.
• Obtain FDA approval for the Acclaim CI (anticipated late 2027 or early 2028).
• Establish a sales, marketing, and distribution infrastructure for the Acclaim CI, initially targeting approximately 30 surgical sites.
• Pursue Conformit Europenne (CE Mark) in the European Union shortly after FDA approval.
• Explore expansion into other international markets such as Australia, Brazil, and parts of Asia.
• Remediate identified material weaknesses in internal control over financial reporting.
• Regain compliance with Nasdaq's $35 million market value of listed securities requirement by February 23, 2026.
• Regain compliance with Nasdaq's $1.00 minimum bid price requirement by May 18, 2026.
• Hold an annual or special meeting of stockholders to obtain Stockholder Approval for the issuance of Common Warrants within 90 days following the Closing Date of the current offering.

Key Dates

Recommendation

Envoy Medical faces severe financial challenges, including a substantial accumulated deficit, ongoing significant net losses, and a 'going concern' opinion from its auditors. The company is also at risk of delisting from Nasdaq due to non-compliance with both market value and minimum bid price requirements. While the Acclaim CI holds promise with its Breakthrough Device Designation and progression to the final stage of clinical trials, it is still years away from potential FDA approval and commercialization, with an identified signal-to-noise issue adding further uncertainty. The current capital raise, while necessary for survival, will result in significant dilution for existing shareholders. Given the high operational and financial risks, coupled with an illiquid stock and ongoing litigation, the investment profile is extremely speculative with a high probability of further capital erosion.

Keywords

Envoy Medical, Cochlear Implant, Acclaim CI, Hearing Health, Medical Device, FDA Approval, Clinical Trials, Equity Offering, Warrants, Nasdaq Listing, Financial Performance, Risk Factors, Intellectual Property, Corporate Governance, S-1/A